For patients with widely metastatic head and neck cancer, the goal is palliation or prolongation of life. Recent studies show that immunotherapy provides a reasonable treatment option for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. This presentation will discuss new and emerging treatment options to optimize outcomes for these patients.